Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
OMass Therapeutics, a University of Oxford spin-out developing small-molecule drugs.
Why it matters: The round shows how European biotech investors are concentrating capital on platform-based drug discovery, with OMass's native mass spectrometry approach now funded through Phase 2.
British clinical-stage biopharma company Microbiotica announced the first close of a €42 million Series C round led by British Business Bank.
Why it matters: Microbiotica's Series C first close shows how genomics and machine learning are moving microbiome drug candidates into Phase 2 trials.
London-based Unravel Health raised €2.96 million led by Conduit EIS Impact Fund and Wrightwood.
Why it matters: The round shows how a saliva-based hormone reader is being funded toward early-access devices in 2027, with the same sensing technology already tested on other markers.
Abby Care, an AI-native home care startup that trains family members to become certified.
Why it matters: Abby Care's $82M Series C shows investors backing an AI-native Medicaid provider that trains and pays family caregivers, a model aimed at the home care labor gap.
Nvidia plans minority stakes in four French startups, Doctolib, Genesis AI, Pigment and Entalpic.
Why it matters: Nvidia's planned minority stakes in four French startups show how chip supply and sovereign-AI funding are becoming the same lever in Europe.
Stride, the preventive health membership founded by Olympic medalist Andrew Steele.
Why it matters: Stride's seed round shows how consumer preventive health is being built around lab diagnostics and an AI copilot, with retention as the open question.
Allara raised a $30M round, bringing total funding to $75M, with existing investors Index Ventures and GV increasing their commitments and Camino Partners.
Why it matters: Allara's $30M round and its plan to push AI from intake through treatment show how an insurance-covered virtual clinic intends to scale specialty care.
Scarlet, founded by ex-Babylon Health medical AI engineers, raised a $50M Series B led by Headline.
Why it matters: Scarlet's $50M round shows how AI medical device certification is becoming its own business, with named customers and a regulatory bottleneck spelled out.
Polyphron raised $20M in seed funding led by Quiet Capital, with Haystack, Gradient and Compound participating. The New York company grows donor-defined human tissue in an automated lab.
Why it matters: The interview details how Polyphron pairs lab-grown human tissue with longitudinal data to train predictive models, a concrete look at the tissue-as-verification layer for drug testing.
Wally raised a $25M Series A led by Maveron, with Bling Capital and angel investors including Hims cofounder Jack Abraham.
Why it matters: Wally's flat-fee dental membership and AI-run clinics show how subscription pricing can realign incentives in a fragmented, insurance-driven market.
Whoop closed a $575 million Series G led by Collaborative Fund at a $10.1 billion valuation.
Why it matters: Whoop's $575M Series G at a $10.1B valuation, nearly triple its prior mark, shows how subscription wearables are drawing sovereign funds and health institutions into consumer fitness.
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing
